Events

UK Bioscience Forum w/ Gareth Jones & Peju Oshisanya

Intellectual Property in AI and data technologies

11:45am | 14 October 2020

The competing demands of data creation, data protection and data provision and acquisition pull data IP practice in different ways. How can we manage these competing demands to produce a result that is ultimately most beneficial for patients and the sector?

Speakers:

  • Gareth Jones, VP Intellectual Property at BenevolentAI
  • Dr Nicola Baker-Munton, Chief Executive Officer at Statagem
  • Joe Foster, COO at Mogrify
  • Tim Hoctor, Vice President of Global Professional Services at Elsevier
  • Jule Sigall, Associate General Counsel, Open Innovation, IP Group at Microsoft

→ Register here

Diversity in data for drug discovery and clinical applications

11:45am | 14 October 2020

A lack of diversity in clinical datasets is a known problem for the life sciences industry, and one that must be addressed. In this session, we will discuss what different organisations are doing to address this, and share lessons they have learned from their experiences.

Speakers:

  • Peju Oshisanya MSc, BSc (HONS), Director, Clinical Programme Leader at BenevolentAI
  • Maria Chatzou Dunford, CEO and Co-Founder at Lifebit Biotech
  • Annette Jack, Founder at Egality
  • Dr Jason Mellad, CEO at Start Codon
  • Umang Patel, Clinical Director, Babylon

→ Register here


Peju Oshisanya

Clinical Drug Development Leader & Data Diversity Advocate at BenevolentAI

Peju is an innovative operational strategy expert with over 15 years wide-ranging experience relating to strategic programme leadership, planning and management of clinical trials with responsibility for global clinical programmes. She has extensive experience in working in early drug discovery and exploratory phases focused on the transition of early stage assets to clinical development. She has held leadership positions in programme management responsible for key clinical programmes and assets within Eli Lilly, Sanofi Aventis, Pfizer and Takeda. In her current role at BenevolentAI, she is responsible for driving the asset strategy to maximise the value of both early and late phase drug development programmes.

Gareth Jones

VP Intellectual Property

Gareth Jones is one of the the world's leading intellectual property strategists (IAM Strategy 300). At BenevolentAI he is responsible for IP activities including strategy, portfolio development, competitive intelligence, fundraising and M&A diligence, patent and data licensing, and collaborations. Gareth has worked at IBM, Vodafone, Microsoft, and also at tech startup SwiftKey where he built and scaled IP operations for one of the largest UK tech exits of 2015/2016


More Posts

You Might Also Like

News
ACTT-2 trial results published in the New England Journal of Medicine validate baricitinib’s efficacy in combination with remdesivir in hospitalised COVID-19 patients
Peer-reviewed data from the ACTT-2 further validate BenevolentAI’s hypothesis for baricitinib as a potential COVID-19 treatment.
Jan 15, 2021
Blog
Joanna Shields speaks at the Global Partnership on Artificial Intelligence
BenevolentAI CEO Joanna Shields opened the final plenary of the Global Partnership on Artificial Intelligence (GPAI) summit with a powerful message on the future of AI.
Dec 11, 2020
Blog
BenevolentAI wins Innovation Award at 2020 Scrip Awards
BenevolentAI wins the Innovation Award at the prestigious 2020 Scrip Awards for our work in artificial intelligence applied drug discovery.
Dec 11, 2020
Intern at BenevolentAI part II: what to expect from your internship
What makes the best tech internships? Learn about what our 2020 interns have been up to, and how interning at Benevolent helped their career development.
Dec 2, 2020
Blog
Intern at BenevolentAI part I: meet our 2020 intern cohort
What impactful work did our interns get up to across Engineering, Data Science, ML and business operations this summer? Get to know them and their work in our tech internships blog.
Nov 26, 2020
News
FDA grants Emergency Use Authorisation for baricitinib in hospitalised COVID-19 patients nine months after initial hypothesis was published by BenevolentAI
BenevolentAI scientists first identified baricitinib as a potential treatment for COVID-19 in early February 2020 using Benevolent's AI tools and biomedical knowledge graph.
Nov 20, 2020